GlassScriptPhysician profile
Alexandria Hernandez
NPI 1609546696
$11,051.50
in general payments reported to CMS, 2019-2025
23 companies · $2,661 in 2025
The $2,661 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $192 · 2022: $1,992 · 2023: $3,255 · 2024: $2,950 · 2025: $2,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,862 · Education: $5.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,862.20 |
| Education | $5.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,997.88 | 2022-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $1,551.35 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $1,416.82 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $1,257.63 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $731.13 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $685.33 | 2022-2025 | Auvelity |
| Corium, LLC | $649.05 | 2021-2025 | Azstarys |
| Alkermes, INC. | $555.72 | 2022-2025 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $523.78 | 2022-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $381.61 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $370.93 | 2021-2025 | Abilify Asimtufii, Rexulti |
| Tris Pharma INC | $172.91 | 2021-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $162.47 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $147.61 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $145.74 | 2024-2025 | Fanapt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $77.51 | 2022-2025 | Trintellix |
| Ironshore Pharmaceuticals INC. | $64.73 | 2022-2024 | |
| Bausch Health US, LLC | $45.17 | 2022-2023 | Aplenzin |
| Noven Therapeutics, LLC | $35.08 | 2024 | Secuado, Xelstrym |
| Boston Scientific Corporation | $25.91 | 2025 | General - Pain Management |
| Tempus Ai, INC | $23.06 | 2024 | |
| Indivior INC. | $15.73 | 2025 | Sublocade |
| Biogen, INC. | $14.35 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandria Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.